SANJIVIN share price, P/E, ROE & financials

On 6 Nov 2026, Sanjivani Paranteral was priced at ₹176.75, or 29.2× trailing earnings, against an industry P/E of 28.7×, and the shares are 28% below their 52-week high. It earns ROCE of 16% and ROE of 16%, and sales and net profit grew 25% and 15% a year over 3 years. Debt is 0.28× equity. It is a small-cap company with a market cap of ₹217 Cr, ranked 94th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 17% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹178.85
Day high: ₹180.00
Day low: ₹170.00
Prev. close: ₹176.35
Volume: 7.9K

Health check

2 good · 2 fair · 2 to check

ReturnsBehind
−16.9% over a year, better than 0 of 7 peers.
Price tagIn line
P/E 29.2 vs industry 28.7.
GrowthStrong
Sales +24.6%, profit +14.6% a year over 3 years.
ProfitabilityAverage
ROCE 16.1% vs peer median 17.9%.
Balance sheetStretched
Debt 0.28× equity, interest covered 18.0×, Piotroski 2 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹217 Cr, #94 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹75 Cr · profit ₹8 Cr

Market cap: ₹217 Cr; Small cap
P/E: 29.2; Industry 28.7
Price to book: 4.10; Peers 4.99
Dividend yield: 0.00%
ROE: 15.7%; Peers 14.7%
ROCE: 16.1%; Peers 17.9%
Debt to equity: 0.28; Debt ₹14 Cr
EPS (TTM): ₹6.06
OPM (TTM): 15.9%; Net margin 10.1%
Sales growth: +33.2%; Latest quarter vs a year ago
Profit growth: +39.4%; Latest quarter vs a year ago
Price to sales: 2.91; EV/EBITDA 20.2

Strengths

Quarterly profit up 39.4% on a year ago.
Quarterly sales up 33.2% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Sanjivani Paranteral

Sanjivani Paranteral Limited operates as a pharmaceutical company in India. The company manufactures pharmaceutical products in the form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas, including central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, such as multivitamins; topicals comprising corticosteroids,…

Headquarters: Mumbai
Employees: 43
Sector: Healthcare
ISIN: INE860D01013
Website: sanjivani.co.in

Price range

52 weeks

₹126.00₹244.00

Today

₹170.00₹180.00

Avg volume (3M): 12.5K
1-year return: minus 16.9%
From 52-week high: minus 27.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.87%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.30%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.81%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.59%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.93%	minus 6.6%
SANJIVINSanjivani Paranteral	176.75	plus 0.23%	217	29.2	4.10	16.1%	15.7%	15.9%	24.6%	14.6%	0.00%	minus 16.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.59%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
17.9	15.5	22.1	13.2	23.8
15.2	13.3	18.2	11.6	19.7
2.6	2.2	3.8	1.6	4.2
14.8%	14.5%	17.4%	11.9%	17.5%
0	0.2	0.3	0.6	0.2
0.2	0	0.2	0.3	0.3
0.2	0.2	0.2	0.7	0.7
2.3	2.2	3.7	1.2	3.3
24.8%	25.2%	24.9%	54.4%	25.0%
1.7	1.6	2.8	0.5	2.4
1.41	1.33	2.21	0.49	2.03

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +24.6%
Profit CAGR 3Y: +14.6%
EPS CAGR 3Y: +6.8%
ROE: 15.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
35.2	53.7	69.6	68.3
–	+52.3%	+29.6%	minus 1.9%
29.9	45.5	59.2	57.9
5.3	8.2	10.4	10.4
15.1%	15.3%	14.9%	15.2%
0.4	0.4	1	1
0.2	0.1	0.4	0.6
0.9	0.9	0.6	1.2
0.4	0.1	−0	−0.2
4.9	7.6	10.4	9.4
8.8%	18.6%	21.8%	28.7%
4.5	6.2	8.1	6.8
–	+36.7%	+31.3%	minus 16.2%
4.51	5.28	6.66	5.49

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
10	11.7	11.9	12.3
−13.1	16.2	26.1	36
2.5	1	8.1	14.3
21.6	14.5	32.1	25.4
21	43.4	78.2	88
7.6	9.9	41.1	47.6
–	–	20.6	0.7
0.1	0	0.6	0.1
0.3	9.6	2.4	1.3
13.1	23.9	13.5	38.3
21	43.4	78.2	88

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4.7	−10.7	12.4	−0.1
−1	−12.2	−21.9	−10
−3.7	23.2	10.5	9.8
−0	0.2	0.9	−0.2
−1.1	−3.3	−30.3	−10.2
3.6	−14	−17.9	−10.3
–	–	–	−0.6

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you